Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.

Abstract:

:Individuals infected with human immunodeficiency virus (HIV) have excess risk of developing human papillomavirus (HPV)-related disease. A substantial fraction of HPV-associated cancers is caused by HPV serotypes not included in the currently available vaccines. Among healthy women, both Cervarix(®) (HPV-16/18, GlaxoSmithKline Biologicals, GSK) and Gardasil(®) (HPV-6/11/16/18, Merck) have demonstrated partial cross-protection against certain oncogenic non-vaccine HPV-types. Currently, there are no available data on vaccine-induced cross-protection in men and little is known about cross-reactive immunity after HPV-vaccination of HIV-infected individuals. In an investigator-initiated trial, we randomized 91 HIV-positive men and women to receive vaccination with Cervarix(®) or Gardasil(®). The HPV-DNA status of the participants was determined with pcr before and after immunization. Cross-reactive antibody responses against HPV-31, HPV-33, and HPV-45 were evaluated for up to 12 months using a pseudovirion-based neutralization assay (PBNA). Geometric mean antibody titers (GMTs) were compared among vaccine groups and genders at 7 and 12 months.: Both vaccines induced anti-HPV-31, -33, and -45 neutralizing antibodies in participants who were seronegative and HPV-DNA negative for those types at study entry. Geometric mean antibody titers were comparable between vaccine groups. Interestingly, anti-HPV-31 and -33 antibody titers were higher among women compared with men at 7 and 12 months.: In conclusion, both licensed HPV-vaccines induced cross-neutralizing antibodies against frequent oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults, and women had greater serological responses against HPV-31 and -33 compared with men.

journal_name

Hum Vaccin Immunother

authors

Toft L,Tolstrup M,Müller M,Sehr P,Bonde J,Storgaard M,Østergaard L,Søgaard OS

doi

10.4161/hv.27925

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

1147-54

issue

5

eissn

2164-5515

issn

2164-554X

pii

27925

journal_volume

10

pub_type

杂志文章,随机对照试验
  • A monoclonal antibody to an abrin chimera recognizing a unique epitope on abrin A chain confers protection from abrin-induced lethality.

    abstract::Abrin, obtained from the seeds of Abrus precatorius plant, is a potent toxin belonging to the family of type II ribosome-inactivating proteins. Recently, a recombinant vaccine consisting of the A subunits of abrin and its homolog Abrus precatorius agglutinin (APA) was demonstrated to protect mice from abrin lethality....

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1067741

    authors: Kumar MS,Karande AA

    更新日期:2016-01-01 00:00:00

  • The cellular and humoral immune response to influenza vaccination is comparable in asthmatic and healthy subjects.

    abstract::Annual influenza vaccination is recommended as a preventive measure for all patients with asthma since asthma exacerbations in children and adults are associated to viral infections including influenza. There is concern about the adequate immune response in asthmatics with ICS treatment. The production of antibodies t...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1759995

    authors: Velasco-Medina AA,García-León ML,Velázquez-Sámano G,Wong-Chew RM

    更新日期:2020-05-21 00:00:00

  • Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.

    abstract::A previous phase 3, randomized, multicenter study showed the immunogenicity of a primary vaccination of subjects aged 11 to 17 years with the quadrivalent meningococcal vaccine conjugated to tetanus toxoid (MenACWY-TT) or the quadrivalent meningococcal polysaccharide vaccine (MenACWY-PS). This extension study evaluate...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1744363

    authors: Quiambao B,Peyrani P,Li P,Cutler MW,Van Der Wielen M,Perez JL,Webber C

    更新日期:2020-06-02 00:00:00

  • Influenza vaccine effectiveness assessment through sentinel virological data in three post-pandemic seasons.

    abstract::Influenza vaccination aims at reducing the incidence of serious disease, complications and death among those with the most risk of severe influenza disease. Influenza vaccine effectiveness (VE) through sentinel surveillance data from the PIDIRAC program (Daily Acute Respiratory Infection Surveillance of Catalonia) dur...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.36155

    authors: Torner N,Martínez A,Basile L,Marcos MA,Antón A,Mar Mosquera M,Isanta R,Cabezas C,Jané M,Domínguez A,Program Of Catalonia TP

    更新日期:2015-01-01 00:00:00

  • Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9.

    abstract::High-risk human papillomavirus (HPV) types are responsible for nearly all cases of cervical cancers. Cervarix® and Gardasil® 9 are the current prophylactic vaccines available that protect against the majority of HPVs associated with cancer. Although these vaccines are highly effective, HPV vaccine implementation has b...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1593727

    authors: Kunda NK,Peabody J,Zhai L,Price DN,Chackerian B,Tumban E,Muttil P

    更新日期:2019-01-01 00:00:00

  • Adolescent vaccines: Need special focus in India.

    abstract::WHO defines adolescence age between 10 to 19 years. In India, there are 243 million adolescents which constitute 21 per cent of the total population. The global burden of disease in adolescents (2011) reports that the total number of disability adjusted life years (DALYs) worldwide among adolescents were 230 million w...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.29757

    authors: Verma R,Khanna P,Chawla S

    更新日期:2015-01-01 00:00:00

  • Penta is associated with an increased female-male mortality ratio: cohort study from Bangladesh.

    abstract::Diphtheria-tetanus-pertussis (DTP) vaccine may be associated with excess female deaths. There are few studies of possible nonspecific effects of the DTP-containing vaccine Penta (DTP-hepatitis B-Haemophilus influenzae type b). We therefore investigated whether Penta vaccinations were associated with excess female deat...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1763084

    authors: Hanifi SMA,Biering-Sørensen S,Jensen AKG,Aaby P,Bhuiya A

    更新日期:2020-06-23 00:00:00

  • High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study.

    abstract::In patients undergoing immunotherapy, the quality of the immune response is reduced, which may negatively affect the efficacy of vaccination. This study was conducted in order to evaluate the efficacy of the hepatitis B virus (HBV) vaccine in patients using immunomodulators. Seronegative patients for HBV who were usin...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1574151

    authors: Haykir Solay A,Eser F

    更新日期:2019-01-01 00:00:00

  • BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant.

    abstract::Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (BBIQ) was reported to be a highly active TLR7 agonist but...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1710409

    authors: Kaushik D,Dhingra S,Patil MT,Piplani S,Khanna V,Honda-Okubo Y,Li L,Fung J,Sakala IG,Salunke DB,Petrovsky N

    更新日期:2020-08-02 00:00:00

  • Evaluation of immunogen delivery by DNA immunization using non-invasive bioluminescence imaging.

    abstract::The efficacy of DNA vaccines is highly dependent on the methods used for their delivery and the choice of delivery sites/targets for gene injection, pointing at the necessity of a strict control over the gene delivery process. Here, we have investigated the effect of the injection site on gene expression and immunogen...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.25561

    authors: Petkov SP,Heuts F,Krotova OA,Kilpelainen A,Engström G,Starodubova ES,Isaguliants MG

    更新日期:2013-10-01 00:00:00

  • Are cases of mumps in vaccinated patients attributable to mismatches in both vaccine T-cell and B-cell epitopes?: An immunoinformatic analysis.

    abstract::Resurgent mumps outbreaks have raised questions about the current efficacy of mumps vaccines. We have applied immunoinformatics techniques based on principal component analysis to evaluate patterns in predicted B-cell linear epitopes, MHC binding affinity and cathepsin cleavage in the hemagglutinin neuraminidase prote...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.27139

    authors: Homan EJ,Bremel RD

    更新日期:2014-01-01 00:00:00

  • Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.

    abstract::A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls an...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1403700

    authors: Moreira ED,Giuliano AR,de Hoon J,Iversen OE,Joura EA,Restrepo J,Van Damme P,Vandermeulen C,Ellison MC,Krick A,Shields C,Heiles B,Luxembourg A

    更新日期:2018-02-01 00:00:00

  • What is the cost of delivering routine vaccinations at GP practices in England? A comparative time-driven activity-based costing analysis.

    abstract::Background: The expansion of available vaccines in recent years has increased the overall costs of the vaccine program and put pressure on providers responsible for vaccination. In England in 2016-17, GP practices responsible for vaccinating their local population were paid £227 million. However, the costs to general ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1619403

    authors: Crocker-Buque T,Mohan K,Ramsay M,Edelstein M,Mounier-Jack S

    更新日期:2019-01-01 00:00:00

  • Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterization and RALA complexation.

    abstract::DNA vaccination holds the potential to treat or prevent nearly any immunogenic disease, including cancer. To date, these vaccines have demonstrated limited immunogenicity in vivo due to the absence of a suitable delivery system which can protect DNA from degradation and improve transfection efficiencies in vivo. Recen...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2016.1248008

    authors: Cole G,McCaffrey J,Ali AA,McBride JW,McCrudden CM,Vincente-Perez EM,Donnelly RF,McCarthy HO

    更新日期:2017-01-02 00:00:00

  • Need to take special care of non-responders to hepatitis B vaccination among health-care workers, students and chronic patients.

    abstract::Both our research and that published by Sticchi et al. on immunological memory against hepatitis B virus (HBV) in health-care workers (HCWs) vaccinated as infants or adolescents confirm that in those testing negative after the primary course, one additional (fourth) booster dose is able to elicit an anti-HBs response ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1810495

    authors: Bechini A,Bonanni P,Grazzini M,Paolini D,Arcangeli G,Mucci N,Bini C,Tiscione E,Zanella B,Boccalini S

    更新日期:2020-12-03 00:00:00

  • Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.

    abstract::The study of influenza virus evolution in humans has revealed a significant role of glycosylation profile alterations in the viral glycoproteins - hemagglutinin (HA) and neuraminidase (NA), in the emergence of both seasonal and pandemic strains. Viral antigenic drift can modify the number and location of glycosylation...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1377871

    authors: Cruz E,Cain J,Crossett B,Kayser V

    更新日期:2018-03-04 00:00:00

  • Timeliness of vaccination in infants followed by primary-care pediatricians in France.

    abstract::Vaccination status is more often evaluated by up-to-date vaccination coverage rather than timeliness of immunization. Delaying vaccination may be dangerous during infancy. The aim of this study was to identify the importance of potentially dangerous vaccination delay (previously defined) and determinants of these dela...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1409318

    authors: Bailly AC,Gras P,Lienhardt JF,Requillart JC,Vié-le-Sage F,Martinot A,Dubos F

    更新日期:2018-04-03 00:00:00

  • Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.

    abstract::The 4-component vaccine 4CMenB, developed against invasive disease caused by meningococcal serogroup B, is approved for use in infants in several countries worldwide. 4CMenB is mostly used as 3 + 1 schedule, except for the UK, where a 2 + 1 schedule is used, and where the vaccine showed an effectiveness of 82.9%. Here...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1537756

    authors: Biolchi A,Tomei S,Santini L,Welsch JA,Toneatto D,Gaitatzis N,Bai X,Borrow R,Giuliani MM,Mori E,Pizza M

    更新日期:2019-01-01 00:00:00

  • Tetanus toxoid vaccine: elimination of neonatal tetanus in selected states of India.

    abstract::Tetanus is caused by a neurotoxin produced by Clostridium tetani (C. tetani), a spore-forming bacterium. Infection begins when tetanus spores are introduced into damaged tissue. Tetanus is characterized by muscle rigidity and painful muscle spasms caused by tetanus toxin's blockade of inhibitory neurons that normally ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.21145

    authors: Verma R,Khanna P

    更新日期:2012-10-01 00:00:00

  • Dendritic cell targeted vaccines: Recent progresses and challenges.

    abstract::Dendritic cells (DCs) are known to be a set of morphology, structure and function of heterogeneous professional antigen presenting cells (APCs), as well as the strongest functional antigen presenting cells, which can absorb, process and present antigens. As the key regulators of innate and adaptive immune responses, D...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1105415

    authors: Chen P,Liu X,Sun Y,Zhou P,Wang Y,Zhang Y

    更新日期:2016-03-03 00:00:00

  • Overview of cancer vaccines: considerations for development.

    abstract::Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This is a review dedicated to determine major regulatory and developmental issues around cancer immunotherapeutics. A three pillar approach should be used in setting a development path: discovery platforms and suffi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.20518

    authors: Kudrin A

    更新日期:2012-09-01 00:00:00

  • Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.

    abstract::We report the findings of three randomized, double-blind, placebo-controlled Phase I studies undertaken to support licensure of the liquid formulation of the human G1P[8] rotavirus (RV) vaccine (RIX4414; GlaxoSmithKline Biologicals SA) in China. Healthy adults aged 18-45 y (n=48) and children aged 2-6 y (n=50) receive...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/hv.25076

    authors: Li RC,Li YP,Mo ZJ,Luo D,Huang T,Kong JL,Wang LH,Song NS,Liu A,Zhang H,Liao X,Karkada N,Han HH

    更新日期:2013-08-01 00:00:00

  • Reliability and validity of a survey to identify vaccine hesitancy among parents in Changxing county, Zhejiang province.

    abstract:BACKGROUND:To evaluate the validity and reliability of a survey to identify vaccine hesitancy among parents. METHODS:Cross-sectional survey of parents of 19-35 month old children was conducted in Changxing County, Zhejiang Province, through a questionnaire developed for the survey of the vaccine hesitancy. Construct v...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1572409

    authors: Hu Y,Chen Y,Liang H,Wang Y

    更新日期:2019-01-01 00:00:00

  • Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.

    abstract::Human papillomavirus is considered the causative factor for cervical cancer, which accounts for approximately 5% of the global cancer burden and more than 600,000 new cases annually that are attributable to HPV infection worldwide. The first-generation prophylactic HPV vaccines, Gardasil® and Cervarix®, were licensed ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2017.1346755

    authors: Zhang Z,Zhang J,Xia N,Zhao Q

    更新日期:2017-10-03 00:00:00

  • Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.

    abstract:UNLABELLED:NmenB vaccine (4CMenB) is now available, but studies on the cost-effectiveness of vaccine introduction in a country outbreak situation are lacking. The aim of this study was to evaluate the cost-effectiveness of 4CMenB in the context of a hypothetical epidemic outbreak in Chile. We analyzed the direct and in...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1010885

    authors: Izquierdo G,Torres JP,Santolaya ME,Valenzuela MT,Vega J,Chomali M

    更新日期:2015-01-01 00:00:00

  • Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults.

    abstract::This was a randomized, placebo-controlled, Phase I/II study conducted in a Japanese cohort to assess the safety and immunogenicity of Clostridium difficile vaccine (the same formulation as that used in the ongoing global Phase III study). Healthy Japanese adults aged 40-75 years were randomized to receive either C. di...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/21645515.2017.1395538

    authors: Matsuoka O,Patel DM,Sasaki S,Oka H,Sasaki T,Pietrobon PJ,Laot T,Bouckenooghe A,Menezes J,de Bruyn G

    更新日期:2018-02-01 00:00:00

  • Evaluating impact of school outreach vaccination programme in Hong Kong influenza season 2018 - 2019.

    abstract::School-based vaccination, as a means to mitigate seasonal influenza outbreak, depends on attaining adequate coverage rate. We evaluated the potential of a fully subsidized school outreach vaccination (SOV) program to achieve epidemic prevention potential in Hong Kong. The purpose of this study was to evaluate the impa...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1678357

    authors: Lau YL,Wong WHS,Hattangdi-Haridas SR,Chow CB

    更新日期:2020-04-02 00:00:00

  • Does intention to recommend HPV vaccines impact HPV vaccination rates?

    abstract::Despite recommendations for routine vaccination, HPV vaccination rates among adolescent females have remained low. The objective of this prospective cohort study was to determine whether clinician intention to recommend HPV vaccines predicts HPV vaccine series initiation among previously unvaccinated 11 to 18 year-old...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/21645515.2014.969613

    authors: Feemster KA,Middleton M,Fiks AG,Winters S,Kinsman SB,Kahn JA

    更新日期:2014-01-01 00:00:00

  • Influenza vaccination coverage rate in children: reasons for a failure and how to go forward.

    abstract::Based on an increasingly extensive literature expressing the large interest in the field, this paper gives an overview of different aspects of influenza prevention in children. It relies on paradoxes. First, the heaviest part of the burden is well demonstrated in the youngest infants by numerous epidemiological data e...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.8.1.18278

    authors: Olivier CW

    更新日期:2012-01-01 00:00:00

  • Rubella vaccine: new horizon in prevention of congenital rubella syndrome in the India.

    abstract::Rubella is a contagious viral disease, which mainly affects the fetus, if the mother is infected in the 1st trimester of her pregnancy. All adolescent girls (aged 11 to 19 y) and women of childbearing age are at risk of developing rubella. This disease is mild and self-limiting, and incubation period is 2-3 weeks. Hum...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.19584

    authors: Verma R,Khanna P,Chawla S

    更新日期:2012-06-01 00:00:00